Welcome to our dedicated page for Can-Fite BioPharma news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite (NYSE American: CANF) completed patient enrollment in its multicenter, open-label Phase 2a study of Namodenoson in advanced pancreatic adenocarcinoma on Jan 20, 2026. The trial evaluates safety (primary endpoint), clinical activity, and pharmacokinetics with oral Namodenoson 25 mg twice daily in continuous 28-day cycles. To date the drug has demonstrated a favorable safety profile. The study is led by Prof. Salomon Stemmer at Davidoff Center, Rabin Medical Center. Can-Fite expects top-line efficacy data in Q3 2026. Namodenoson is a selective A3 adenosine receptor agonist with preclinical anti-tumor activity and has received FDA Orphan Drug Designation for pancreatic cancer.
Can-Fite (NYSE American: CANF) announced that the Brazilian Patent Office granted Patent No. BR112015002697-4 for “Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction” on Dec. 26, 2025.
The patent provides intellectual‑property protection in Brazil for Can‑Fite’s A3AR agonists for sexual dysfunction, complements the company’s global patent portfolio, and may support future partnering or commercialization opportunities in Latin America. Can‑Fite cites preclinical and clinical data suggesting A3AR activation may modulate signaling related to erectile and sexual function.
Can-Fite (NYSE American: CANF) announced a 1-for-3,000 reverse split of ordinary shares following shareholder approval on November 10, 2025.
The split will be recorded on the Tel-Aviv Stock Exchange on January 2, 2026, with first TASE trading of consolidated shares on January 5, 2026. Concurrently the ADS ratio will change from 1 ADS = 300 ordinary shares to 1 ADS = 2 ordinary shares, effective on the NYSE American on January 5, 2026, requiring an exchange of every 20 ADS for 1 new ADS.
The company will reduce authorized ordinary shares from 42,000,000,000 to 14,000,000 and issue no fractional ordinary shares (rounded up); ADS fractional entitlements will be aggregated and sold by the depositary bank. New CUSIP: 13471N409.
Can-Fite BioPharma (NYSE American: CANF) provided a clinical and financial update on Dec 16, 2025. Key clinical programs: Namodenoson is enrolling a pivotal Phase III in advanced hepatocellular carcinoma (Child-Pugh B7) with an interim analysis ~Q4 2026, a Phase IIb in MASH (following positive Phase IIa published data), and a Phase IIa in pancreatic cancer with data expected Q2 2026. Piclidenoson is enrolling a pivotal Phase III in psoriasis with an interim readout ~Q2 2026. Financials: cash and short-term deposits were $6.45M as of June 30, 2025; the company raised $5M in a July 28, 2025 public offering and $2.2M via ATM in Nov 2025.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Motti Farbstein will present at NobleCon21 on Wednesday, December 3, 2025 at 12:30 PM ET in Boca Raton, Florida.
The presentation will cover the company's advanced-stage drug development pipeline, including listed trials: Phase III liver cancer, Phase IIa pancreatic cancer, Phase III psoriasis, Phase IIb MASH, and an upcoming Phase II in Lowe syndrome. The CEO will also hold 1x1 investor meetings.
Can-Fite noted existing out-licensing and global distribution agreements worth up to $130 million for pharma indications and up to $325 million for veterinary indications. A high-definition webcast will be available the following day and archived for 90 days on Can-Fite, NobleCon, and Channelchek websites.
Can-Fite (NYSE American: CANF) said it will attend BioFIT 2025 in Strasbourg on Dec 2–3, 2025 to pursue veterinary partnerships for Namodenoson, its Phase III anti-cancer candidate.
The company cites prior BioFIT participation that led to a Piclidenoson veterinary deal with Vetbiolix, an agreement noted as potentially worth an estimated $325 million in royalty revenues. Can-Fite will hold partnering meetings with major animal-health companies including Elanco and Zoetis to explore bringing Namodenoson into veterinary oncology.
Namodenoson has shown strong anti-tumor activity, a reported complete response in a human liver cancer patient, and an excellent safety profile; human trials include a Phase III liver cancer study and a Phase II pancreatic study.
Can-Fite (NYSE:CANF) received a Notice of Allowance in Brazil for a patent titled “An A3 Adenosine Receptor Ligands For Use in Treatment of a Sexual Dysfunction,” extending IP protection for its CF602 erectile dysfunction candidate beyond previously granted U.S. and European patents.
The release highlights a $3.2 billion ED market, where 30%–35% of patients are non-responders to PDE5 inhibitors and an estimated 16 million U.S. men with diabetes may be contraindicated for those drugs. Preclinical results in a diabetic rat model reported a single-dose full erectile recovery, increased arterial blood flow, and dose-dependent improvements in intracavernosal pressure, smooth muscle/collagen ratio, VEGF, and eNOS.
Can-Fite (NYSE American: CANF) reported that a patient with advanced hepatocellular carcinoma treated with Namodenoson reached 9 years overall survival with a complete response and remains cancer-free while on compassionate use treatment.
The company is enrolling a pivotal Phase III HCC study in Israel, Europe and the U.S.; the protocol was agreed with the FDA and EMA. Namodenoson holds Orphan Drug status from both agencies and Fast Track status from the FDA. A compassionate use program is active in Israel and Romania.
Can-Fite BioPharma (NYSE American: CANF) reported a significant clinical breakthrough in their compassionate use program for Namodenoson in decompensated liver cirrhosis. A patient demonstrated complete resolution of esophageal varices, a severe complication of advanced liver disease that can cause life-threatening bleeding.
The treatment shows potential disease-modifying effects, as confirmed by endoscopic evaluation. Namodenoson is currently in a Phase III clinical trial for hepatocellular carcinoma (HCC) in patients with advanced liver disease. The development is particularly significant given that approximately 10.6 million people globally were affected by decompensated cirrhosis as of 2017, with the U.S. liver cirrhosis treatment market expected to reach $15 billion by 2030.
Can-Fite BioPharma (NYSE American: CANF) reported H1 2025 financial results and clinical updates. The company reached significant milestones in its drug development programs, with Namodenoson achieving over 50% enrollment in its Phase 2a pancreatic cancer trial and receiving FDA compassionate use approval. A breakthrough UCLA study demonstrated Piclidenoson's potential for treating vascular dementia, targeting a $6 billion market.
Financial results showed revenues of $0.20 million, down 36.07% year-over-year. Net loss increased to $4.87 million from $3.95 million in H1 2024. The company held $6.45 million in cash and equivalents as of June 30, 2025, and completed a $5 million public offering in July 2025.